Hormonal Contraceptives, Intrauterine Devices, Gonadotropin-releasing Hormone Analogues and Testosterone: Menstrual Suppression in Special Adolescent Populations. [Review]
Citation: Journal of Pediatric & Adolescent Gynecology. 32(5S):S23-S29, 2019 Sep.PMID: 30980941Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and Gynecology/Pediatric and AdolescentForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Disabled Persons | *Menstruation/de [Drug Effects] | *Neoplasms/co [Complications] | *Transgender Persons/px [Psychology] | Adolescent | Attitude of Health Personnel | Contraceptives, Oral, Hormonal/ad [Administration & Dosage] | Female | Gonadotropin-Releasing Hormone/ad [Administration & Dosage] | Humans | Intrauterine Devices | Male | Testosterone/ad [Administration & Dosage]Year: 2019ISSN:- 1083-3188
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 30980941 | Available | 30980941 |
Menstrual suppression (the use of hormonal contraceptive methods to eliminate or significantly decrease the frequency of menstrual cycles) is frequently used in the adolescent population for the management of menstrual symptoms such as heavy or painful periods, premenstrual syndrome, menstrual migraines, or even for patient preference. However, in cases of menstrual suppression in special populations additional risks and benefits need to be considered. The purpose of this article is to review the options and medical considerations for menstrual suppression in patients undergoing chemotherapy who might be at risk of abnormal uterine bleeding, those with intellectual or physical disability, and transgender and gender nonbinary individuals. Copyright (c) 2019. Published by Elsevier Inc.
English